Articles from Salipro Biotech AB

New U.S. patent secures long term protection for the Salipro® platform technologies, extending exclusivity until 2042 and reinforcing the company’s position as a premier partner for drug discovery against challenging drug targets

The two new patents expand protection for Salipro Biotech's proprietary technology for stabilizing and extracting challenging membrane proteins, crucial for developing therapeutics against high-value drug targets like GPCRs and Ion Channels

The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable and accelerate the development of novel therapeutics.

Salipro Biotech and Icosagen announce the initiation of a multi-target collaboration for the discovery and characterization of monoclonal antibodies against several GPCRs and SLC transporters.

The collaboration leverages Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilize a challenging drug target to investigate the pharmacological characteristics of a compound from Sumitomo Pharma’s discovery program.

Salipro Biotech obtains granted patent in Japan, protecting its proprietary Salipro® platform technology to enable the development of therapeutics against challenging drug targets, including GPCRs, SLCs and Ion Channels.

The two biotech companies report that they have successfully screened and identified several small molecule compounds that bind to a challenging membrane protein drug target.